


Grounded in Innovation. Powered by Collaboration.

At Hemostasis, LLC, we partner with leading physicians to develop innovative technologies designed to optimize usability and efficacy, to improve patient outcomes and enhance overall patient care. We strive to continuously innovate and improve.

Innovative Products that Support Hospital and Surgical Care Around the Globe.



PosiSep® PosiSep® X

Dissolvable hemostat dressings/intranasal splints

Constructed from our proprietary NOCC chitosan polymer technology, the PosiSep® and PosiSep® X hemostat dressing/intranasal splint provides both superior performance and patient comfort. PosiSep® X is unique in its placement, ability to conform to any sinus anatomy, and even in the way it is most easily removed.



OUR PRODUCTS

PosiSep® PosiSep® X

Along with a variety of bleeding control and wound healing technologies, Hemostasis is a leading manufacturer of the groundbreaking product PosiSep® brands of sinus spacer/hemostat technologies within the ENT space.

Our PosiSep® X comes as a firm sponge and expands after placement in the sinus cavity and hydration with saline and provides longer term separation (7-10 days) while our PosiSep® hemostat spacer provides a faster dissolving, faster clearing product with 2-3 days of tissue separation.



OUR TECHNOLOGIES

Chitosan Our Chitosan Based Technologies

One of Hemostasis' core technologies is a naturally occurring polysaccharide derivative of deacetylated chitin, Chitosan. Chitin can be obtained from the structure of crustaceans (crabs, shrimps, diatoms, etc.) and Chitosan is derived from chitin using various proprietary processes of sodium hydroxide washing to obtain the desired degree of deacetylation and molecular weight.

Hemostasis has developed a variety of chitosan-based technologies, including NO carboxymethylated chitosan in addition to other proprietary modified chitosans. Depending on the surgical application, different chitosan technologies may be utilised to suit the individual requirements or preferences of the surgeon.



STUDIES

of Chitosan Based Technologies

Scientists and surgeons have evaluated our novel chitosan platform for healing and hemostasis in the sinus cavity as well as severe bleeding in porcine femoral and acute liver models. Several studies have been published regarding its effectiveness in the following lethal injury models:

Use of a modified chitosan dressing in a hypothermic Coagulopathic grade V liver injury model.

Evaluation of a new hemostatic agent in a porcine grade V liver injury mode.

A Novel Polymeric absorption enhancer for the oral delivery of macromolecules.

Development of an injectable sustained release formulation of morphine rat model.

Preventions of pericardial adhesions with NOCC in rabbit model – Journal of INvestigative Surgery

Prevention of post op adhesions with the chitin derivative NOCC – Krause-ZAzanis

Prevention of post op peritoneal adhesions by NOCC – Kenndy-Lee Halifax

Prevention of postsurgical adhesions with NOCC – Costain-Kennedy-Ciona-TimLee

Rat Hypersensitivity Study

Reduction in post op surgical adhesion formation after cardiac surgery – Acquired Cardiovascular Disease

Reduction in post surgical adhesions formation after cardiac surgery in rabbit model – cardiopulmonary Support and Phys

Reduction in postop adhesions formation after an abdominal operations – Halifax Novascotia

Reduction of post operative adhesions by NO-Carboxymethylchitosan – A Pilot Study – Journal of the American Association of Gyn Lap 2004

Reduction of postop adhesions by NOCC a pilot study – Fertility and Sterility

HEMOSTASIS, LLC

MedTech Center
5000 Township Parkway
Saint Paul, MN 55110 USA

UK Distributor | Minim Healthcare Ltd

